Serum visfatin concentration and endothelial dysfunction in chronic kidney disease

Nephrology Dialysis Transplantation

Volumn 23, Issue 3, 2008, Pages 959-965

  Yilmaz, Mahmut Ilker ^a,b   Saglam, Mutlu ^a   Carrero, Juan Jesus ^b   Qureshi, Abdul Rashid ^b   Caglar, Kayser ^a   Eyileten, Tayfun ^a   Sonmez, Alper ^a   Cakir, Erdinc ^a   Yenicesu, Mujdat ^a   Lindholm, Bengt ^b   Stenvinkel, Peter ^b   Axelsson, Jonas ^b  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adiponectin; Flow mediated dilation; Insulin resistance; Visfatin

Indexed keywords

ADIPONECTIN; VISFATIN; BIOLOGICAL MARKER; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD FLOW; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TURKEY (REPUBLIC); VASODILATATION; BLOOD; CASE CONTROL STUDY; CHRONIC DISEASE; HOSPITALIZATION; INFLAMMATION; KIDNEY DISEASE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ADIPONECTIN; ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHRONIC DISEASE; ENDOTHELIUM, VASCULAR; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INFLAMMATION; INSULIN RESISTANCE; KIDNEY DISEASES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; SEVERITY OF ILLNESS INDEX; VASODILATION;

EID: 42449149616     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm727     Document Type: Article

References (27)

1. Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol 2004; 15: 1983-1992
2. Suwaidi JA, Hamasaki S, Higano ST et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948-954
3. Takami R, Takeda N, Hayashi M et al. Body fatness and fat distribution as predictors of metabolic abnormalities and early carotid atherosclerosis. Diabetes Care 2001; 24: 1248-1252
4. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881-887
5. Wang TD, Chen WJ, Cheng WC et al. Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome. Am J Cardiol 2006; 98: 1057-1062
6. Axelsson J, Heimburger O, Stenvinkel P. Adipose tissue and inflammation in chronic kidney disease. Contrib Nephrol 2006; 151: 165-174
7. Chudek J, Adamczak M, Nieszporek T, Wiecek A. The adipose tissue as an endocrine organ-a nephrologists' perspective. Contrib Nephrol 2006; 151: 70-90
8. Wassink AM, Olijhoek JK, Visseren FL. The metabolic syndrome: metabolic changes with vascular consequences. Eur J Clin Invest 2007; 37: 8-17
9. Malyszko J, Malyszko JS, Brzosko S et al. Adiponectin is related to CD146, a novel marker of endothelial cell activation/injury in chronic renal failure and peritoneally dialyzed patients. J Clin Endocrinol Metab 2004; 89: 4620-4627
10. Fukuhara A, Matsuda M, Nishizawa M et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-430
11. Moschen AR, Kaser A, Enrich B et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007; 178: 1748-1758
12. Axelsson J, Witasp A, Carrero JJ et al. Circulating levels of visfatin/Pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am J Kidney Dis 2007; 49: 237-244
13. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2004; 42: S1-S202
14. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 1999; 130: 461-470
15. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
16. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
17. Celermajer DS, Sorensen KE, Gooch VM et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-1115
18. Peralta CA, Shlipak MG, Fan D et al. Risks for end-stage renal disease, cardiovascular events, and death in Hispanic versus non-Hispanic white adults with chronic kidney disease. J Am Soc Nephrol 2006; 17: 2892-2899
19. Fernandez-Fresnedo G, Rodrigo E, de Francisco AL et al. Role of pulse pressure on cardiovascular risk in chronic kidney disease patients. J Am Soc Nephrol 2006; 17: S246-S249
20. Dogra G, Irish A, Chan D, Watts G. Insulin resistance, inflammation, and blood pressure determine vascular dysfunction in CKD. Am J Kidney Dis 2006; 48: 926-934
21. Ohashi K, Kihara S, Ouchi N et al. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 2006; 47: 1108-1116
22. Ouchi N, Ohishi M, Kihara S et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003; 42: 231-234
23. Marchlewska A, Stenvinkel P, Lindholm B et al. Reduced gene expression of adiponectin in fat tissue from patients with end-stage renal disease. Kidney Int 2004; 66: 46-50
24. Zoccali C, Mallamaci F, Tripepi G et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 134-141
25. Axelsson J, Bergsten A, Qureshi AR et al. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int 2006; 69: 596-604
26. Berndt J, Kloting N, Kralisch S et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005; 54: 2911-2916
27. Wang T, Zhang X, Bheda P et al. Structure of Nampt/PBEF/visfatin, a mammalian NAD+ biosynthetic enzyme. Nat Struct Mol Biol 2006; 13: 661-662